Targets & Mechanisms: AD vaccine redux 

 

Table 1. Alzheimer's disease vaccine pipeline. At least seven vaccines against b-amyloid (Ab) are in preclinical through Phase II testing to prevent AD.
Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Status

Johnson & Johnson (NYSE:JNJ)/Pfizer Inc. (NYSE:PFE)

PF-5236806 (ACC-001)

Ab-related immunotherapeutic conjugate

Phase II

Affiris AG/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)

AD02

Vaccine against a peptide mimic of Ab

Phase II

Cytos Biotechnology AG (SIX:CYTN)/Novartis AG (NYSE:NVS; SIX:NOVN)

CAD106

Vaccine against Ab

Phase II

AC Immune S.A.

ACI-24

Vaccine that stimulates the production of b-sheet conformation-specific antibodies

Phase I/II

Affiris/GlaxoSmithKline

AD03

Vaccine against a peptide mimic of Ab

Phase I

Intellect Neurosciences Inc. (OTCBB:ILNS)

RV-01

Four-amino-acid amino-terminal fragment of Ab conjugated to tetanus toxoid

Preclinical

Mercia Pharma Inc.

MER5101

Fifteen-amino-acid amino-terminal fragment of Ab conjugated to diphtheria toxoid in an anti-inflammatory oil-based adjuvant

Preclinical